Cambridge Enterprise and the University of Cambridge Enterprise Fund, managed by Parkwalk, have invested £500k in Polypharmakos Limited, a spin-out from the university and the Royal Botanic Gardens, Kew.
Polypharmakos’ mission is to screen natural-product sources of plant, fungal and insect origin for antimicrobially active substances with novel mechanisms of action and to develop them to address the emerging global antimicrobial resistance (AMR) crisis.
Comments